New cases of acute hepatitis C have increased rapidly in the US since 2010, and have most often been associated with injection drug use. Efforts to diagnose and link individuals to care need to significantly increase to reduce the rates of acute HCV infection. The recommended testing algorithm for the diagnosis of HCV requires an initial screen with an HCV antibody test which, if reactive, should be followed by an HCV Nucleic Acid Test (NAT) to detect the viral RNA present in a person with a current infection. This webinar will share the experiences of two jurisdictions that have implemented HCV RNA testing. The presentations will highlight the collaborations between the public health laboratory and the health department from planning to implementation and sustaining testing.